BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AU/UGA Medical Partnership - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AU/UGA Medical Partnership
X-ORIGINAL-URL:https://medicalpartnership.usg.edu
X-WR-CALDESC:Events for AU/UGA Medical Partnership
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231206T120000
DTEND;TZID=America/New_York:20231206T130000
DTSTAMP:20231129T055532Z
CREATED:20231128T234556Z
LAST-MODIFIED:20231129T055532Z
UID:4404-1701864000-1701867600@medicalpartnership.usg.edu
SUMMARY:MOD Series 👁️ IL-6 Trans-Signaling: A Novel Therapeutic Target for Diabetic Retinopathy
DESCRIPTION:Students & Faculty please join us for the\nMechanisms of Disease\n2023-2024 SEMINAR SERIES\n \nPresented by\nShruti Sharma\, PhD\n\nAssociate Professor \nCenter of Biotechnology & Genomic Medicine \nDepartment of Ophthalmology \nMedical College of Georgia at Augusta University \nPersonal Statement: \nDr. Shruti Sharma is an Associate Professor in the Center of Biotechnology and Genomic Medicine\, Department of Ophthalmology at the Medical College of Georgia at Augusta University. Her major research interests are in understanding the role of vascular dysfunction in the microvascular complications of diabetes. Currently\, her lab is focused on studying the inflammation-induced pathologies in diabetic retinopathy (DR)\, and has established the role of interleukin-6 trans-signaling as a novel therapeutic target in DR by using the drug-sgp130Fc. Our in-vitro and animal studies have shown that this drug can prevent inflammation\, oxidative stress\, mitochondrial damage\, and apoptosis associated with diabetic retinopathy. \nLocation: Russell Hall\, Room 228\n 
URL:https://medicalpartnership.usg.edu/event/mod-series-%f0%9f%91%81%ef%b8%8f-il-6-trans-signaling-a-novel-therapeutic-target-for-diabetic-retinopathy/
LOCATION:Russell Hall\, 1425 Prince Avenue\, Athens\, GA\, 30602\, United States
CATEGORIES:Faculty,Staff
END:VEVENT
END:VCALENDAR